$FATE News

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026

Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Fate Therapeutics Appoints Laura Hamill to Board of Directors

H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT

HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatology

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate